FK506 and anti-CD40 ligand in peripheral nerve allotransplantation

Restorative Neurology and Neuroscience

Volumn 23, Issue 3-4, 2005, Pages 237-249

  Brenner, Michael J ^a   Mackinnon, Susan E ^a,b   Rickman, Susan R ^a   Jaramillo, Andrés ^a   Tung, Thomas H H ^a   Hunter, Daniel A ^a   Mohanakumar, T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Urologic Surgery   (United States)

Author keywords

Anti CD40 ligand; FK506; Immune tolerance; Nerve allograft; Nerve regeneration

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOSPORIN A; GAMMA INTERFERON; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG MEGADOSE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MOUSE; NERVE GRAFT; NERVE REGENERATION; NERVE TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; TIBIAL NERVE;

ANIMALS; ANTIBODIES, MONOCLONAL; CD40 LIGAND; CYTOLOGICAL TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; NERVE FIBERS; NERVE REGENERATION; RANDOM ALLOCATION; RECOVERY OF FUNCTION; TACROLIMUS; TIBIAL NERVE; TRANSPLANTATION, HOMOLOGOUS;

EID: 23644445977     PISSN: 09226028     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. A. Atchabahian, S.E. Mackinnon and D.A. Hunter, Cold preservation of nerve grafts decreases expression of ICAM-1 and class II MHC antigens, Journal of Reconstructive Microsurgery 15 (1999), 307-311.
2. J.R. Bain, S.E. Mackinnon, A.R. Hudson, R.E. Falk, J.A. Falk and D.A. Hunter, The peripheral nerve allograft: a dose-response curve in the rat immunosuppressed with cyclosporin A, Plastic & Reconstructive Surgery 82 (1988), 447-457.
3. J.R. Bain, S.E. Mackinnon, A.R. Hudson, R.E. Falk, J.A. Falk and D.A. Hunter, The peripheral nerve allograft: an assessment of regeneration across nerve allografts in rats immunosuppressed with cyclosporin A, Plastic & Reconstructive Surgery 82 (1988), 1052-1066.
4. J.R. Bain, S.E. Mackinnon, A.R. Hudson, J. Wade, P. Evans, A. Makino and D. Hunter, The peripheral nerve allograft in the primate immunosuppressed with Cyclosporin A: I. Histologic and electrophysiologic assessment, Plastic & Reconstructive Surgery 90 (1992), 1036-1046.
5. J.H. Barker, C.G. Francois, J.M. Frank and C. Maldonado, Composite tissue allotransplantation, Transplantation 73 (2002), 832-835.
6. R.B. Birge, S. Wadsworth, R. Akakura, H. Abeysinghe, R. Kanojia, M. MacIelag, J. Desbarats, M. Escalante, K. Singh, S. Sundarababu, K. Parris, G. Childs, A. August, J. Siekierka and D.E. Weinstein, A role for schwann cells in the neuroregenerative effects of a non-immunosuppressive fk506 derivative, jnj460, Neuroscience 124 (2004), 351-366.
7. P. Brams, A. Black, E.A. Padlan, K. Hariharan, J. Leonard, K. Chambers-Slater, R.J. Noelle and R. Newman, A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation, International Immunopharmacology 1 (2001), 277-294.
8. M.J. Brenner, I.K. Fox, D.H. Kawamura, V.M. Yu, J.B. Lowe, III., D.A. Hunter and S.E. Mackinnon, Delayed nerve repair is associated with diminished neuroenhancement by FK506, Laryngoscope 114 (2004), 570-576.
9. M.J. Brenner, J.N. Jensen, J.B. Lowe, III., I.K. Fox, D.A. Hunter, T.M. Myckatyn, T. Mohanakumar and S.E. Mackinnon, Anti-CD40 ligand Antibody permits regeneration through peripheral nerve allografts in a non-human primate model, Plastic & Reconstructive Surgery (2004).
10. M.J. Brenner, T.H.H. Tung, S.E. Mackinnon, T.M. Myckatyn, D.A. Hunter and T. Mohanakumar, Anti-CD40 ligand monoclonal antibody induces a permissive state, but not tolerance, for murine peripheral nerve allografts, Experimental Neurology 186 (2004), 59-69.
11. M.J. Brenner, T.H. Tung, J.N. Jensen and S.E. Mackinnon, The spectrum of complications of immunosuppression: is the time right for hand transplantation? Journal of Bone & Joint Surgery - American 84-A (2002), 1861-1870.
12. A.L. Burnett and R.E. Becker, Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury, Journal of Urology 171 (2004), 495-500.
13. R. Buttemeyer, U. Rao and N.F. Jones, Peripheral nerve allograft transplantation with FK506: functional, histological, and immunological results before and after discontinuation of immunosuppression, Annals of Plastic Surgery 35 (1995), 396-401.
14. A. Chandraker, M.E. Russell, T. Glysing-Jensen, T.A. Willett and M.H. Sayegh, T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen, Transplantation 63 (1997), 1053-1058.
15. R. Chunasuwankul, C. Ayrout, Z. Dereli, A. Gal, M. Lanzetta and E. Owen, Low dose discontinued FK506 treatment enhances peripheral nerve regeneration, Int. Surg. 87 (2002), 274-278.
16. G. Ciancio, G.W. Burke, J.J. Gaynor, A. Mattiazzi, D. Roth, W. Kupin, M. Nicolas, P. Ruiz, A. Rosen and J. Miller, A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year, Transplantation 77 (2004), 244-251.
17. M.D. Denton, C.C. Magee and M.H. Sayegh, Immunosuppressive strategies in transplantation, Lancet 353 (1999), 1083-1091.
18. M.D. Denton, R.M. Reul, V.R. Dharnidharka, J.C. Fang, P. Ganz and D.M. Briscoe, Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection, Pediatric Transplantation 2 (1998), 6-15.
19. V.M. Dong, X. Yuan, A.J. Coito, A.M. Waaga, M.H. Sayegh and A. Chandraker, Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection, Transplantation 73 (2002), 1310-1317.
20. V.B. Doolabh and S.E. Mackinnon, FK506 accelerates functional recovery following nerve grafting in a rat model, Plastic & Reconstructive Surgery 103 (1999), 1928-1936.
21. C.J. Dunn, A.J. Wagstaff, C.M. Perry, G.L. Plosker and K.L. Goa, Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation, Drugs 61 (2001), 1957-2016.
22. R.A. Ellis, M.J. Brenner, S.E. Mackinnon, T.M. Myckatyn and D.A. Hunter, Use of the mixed lymphocyte reaction to identify sub-immunosuppressive FK-506 levels in mice, Microsurgery 23 (2003), 276-282.
23. E.A. Elster, H. Xu, D.K. Tadaki, S. Montgomery, L.C. Burkly, J.D. Berning, R.E. Baumgartner, F. Cruzata, R. Marx, D.M. Harlan and A.D. Kirk, Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates, Transplantation 72 (2001), 1473-1478.
24. S.M. Ensminger, B.M. Spriewald, O. Witzke, K. Morrison, A. Van Maurik, P.J. Morris, M.L. Rose and K.J. Wood, Intragraft interleukin-4 mRNA expression after short-term CD154 blockade may trigger delayed development of transplant arteriosclerosis in the absence of CD8+ T cells, Transplantation 70 (2000), 955-963.
25. S.M. Ensminger, O. Witzke, B.M. Spriewald, K. Morrison, P.J. Morris, M.L. Rose and K.J. Wood, CD8+ T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade, Transplantation 69 (2000), 2609-2612.
26. D.J. Fox, V.B. Doolabh, S.E. Mackinnon, E.M. Genden and D.A. Hunter, Decreased cyclosporin A requirement with anti-ICAM-1 and anti-LFA-1a in a peripheral nerve allotransplantation model, Restorative Neurology & Neuroscience 15 (1999), 319-326.
27. B.G. Gold, T. Storm-Dickerson and D.R. Austin, The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury, Restorative Neurology & Neuroscience 6 (1994), 287-296.
28. B.G. Gold, FK506 and the role of the immunophilin FKBP-52 in nerve regeneration, Drug Metabolism Reviews 31 (1999), 649-663.
29. B.G. Gold, K. Katoh and T. Storm-Dickerson, The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve, Journal of Neuroscience 15 (1995), 7509-7516.
30. B.G. Gold, J. Voda, X. Yu and H. Gordon, The immunosuppressant FK506 elicits a neuronal heat shock response and protects against acrylamide neuropathy, Experimental Neurology 187 (2004), 160-170.
31. T. Gordon, O. Sulaiman and J.G. Boyd, Experimental strategies to promote functional recovery after peripheral nerve injuries, Journal of the Peripheral Nervous System 8 (2003), 236-250.
32. W.W. Hancock, M.H. Sayegh, X.G. Zheng, R. Peach, P.S. Linsley and L.A. Turka, Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection, Proceedings of the National Academy of Sciences of the United States of America 93 (1996), 13967-13972.
33. B. Hausen, J. Klupp, U. Christians, J.P. Higgins, R.E. Baumgartner, L.E. Hook, S. Friedrich, A. Celnicker and R.E. Morris, Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys, Transplantation 72 (2001), 1128-1137.
34. S.C. Jost, V.B. Doolabh, S.E. Mackinnon, M. Lee and D.A. Hunter, Acceleration of peripheral nerve regeneration following FK506 administration, Restorative Neurology & Neuroscience 17 (2000), 39-44.
35. N. Karamperis, J.V. Povlsen, C. Hojskov, J.H. Poulsen, A.R. Pedersen and K.A. Jorgensen, Comparison of the pharmacokinetics of tacrolimus and cyclosporine at equivalent molecular doses, Transplantation Proceedings 35 (2003), 1314-1318.
36. A.D. Kirk, P.J. Blair, D.K. Tadaki, H. Xu and D.M. Harlan, The role of CD154 in organ transplant rejection and acceptance, Philosophical Transactions of the Royal Society of London - Series B: Biological Sciences 356 (2001), 691-702.
37. A.D. Kirk, L.C. Burkly, D.S. Batty, R.E. Baumgartner, J.D. Berning, K. Buchanan, J.H. Fechner, Jr., R.L. Germond, R.L. Kampen, N.B. Patterson, S.J. Swanson, D.K. Tadaki, C.N. TenHoor, L. White, S.J. Knechtle and D.M. Harlan, Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates, Nature Medicine 5 (1999), 686-693.
38. A.D. Kirk, D.M. Harlan, N.N. Armstrong, T.A. Davis, Y. Dong, G.S. Gray, X. Hong, D. Thomas, J.H. Fechner, Jr. and S.J. Knechtle, CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates, Proceedings of the National Academy of Sciences of the United States of America 94 (1997), 8789-8794.
39. K. Kishimoto, V.M. Dong and M.H. Sayegh, The role of costimulatory molecules as targets for new immunosuppressives in transplantation, Current Opinion in Urology 10 (2000), 57-62.
40. R.J. Knight, R.H. Kerman, S. Zela, H. Podder, C.T. Van Buren, S. Katz and B.D. Kahan, Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation, Transplantation 75 (2003), 1301-1306.
41. C.P. Larsen, D.Z. Alexander, D. Hollenbaugh, E.T. Elwood, S.C. Ritchie, A. Aruffo, R. Hendrix and T.C. Pearson, CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway, Transplantation 61 (1996), 4-9.
42. C.P. Larsen, E.T. Elwood, D.Z. Alexander, S.C. Ritchie, R. Hendrix, C. Tucker-Burden, H.R. Cho, A. Aruffo, D. Hollenbaugh, P.S. Linsley, K.J. Winn and T.C. Pearson, Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways, Nature 381 (1996), 434-438.
43. C.P. Larsen and T.C. Pearson, The CD40 pathway in allograft rejection, acceptance, and tolerance, Current Opinion in Immunology 9 (1997), 641-647.
44. S. Li, M. Thanikachalam, M. Pang, M. Carreno, A. Aitouche and S.M. Pham, Combined host-conditioning with CTLA4-Ig, tacrolimus, anti-lymphocyte serum, and low-dose radiation leads to stable mixed hematopoietic chimerism, Experimental Hematology 29 (2001), 534-541.
45. Y. Li, X.C. Li, X.X. Zheng, A.D. Wells, L.A. Turka and T.B. Strom, Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance, Nature Medicine 5 (1999), 1298-1302.
46. Y. Li, X.X. Zheng, X.C. Li, M.S. Zand and T.B. Strom, Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment, Transplantation 66 (1998), 1387-1388.
47. H. Lin, S.F. Bolling, P.S. Linsley, R.Q. Wei, D. Gordon, C.B. Thompson and L.A. Turka, Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion, Journal of Experimental Medicine 178 (1993), 1801-1806.
48. S.E. Mackinnon, V.B. Doolabh, C.B. Novak and E.P. Trulock, Clinical outcome following nerve allograft transplantation, Plastic and Reconstructive Surgery 107 (2001), 1419-1429.
49. R. Midha, P.J. Evans, S.E. Mackinnon and J.A. Wade, Temporary immunosuppression for peripheral nerve allografts, Transplantation Proceedings 25 (1993), 532-536.
50. S.D. Moffatt and S.M. Metcalfe, FK 506 versus cyclosporine in combination with anti-CD4/CD8 monoclonal antibodies, Transplantation Proceedings 31 (1999), 2740.
51. T.M. Myckatyn, R.A. Ellis, A.G. Grand, S.K. Sen, J.B. Lowe, III., D.A. Hunter and S.E. Mackinnon, The effects of rapamycin in murine peripheral nerve isografts and allografts, Plastic & Reconstructive Surgery 109 (2002), 2405-2417.
52. Y.A. Pan, T. Misgeld, J.W. Lichtman and J.R. Sanes, Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo, Journal of Neuroscience 23 (2003), 11479-11488.
53. N. Parry, A.I. Lazarovits, J. Wang, B. Garcia, P. Luke, S. Poppema and R. Zhong, Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB, Journal of Heart & Lung Transplantation 18 (1999), 441-447.
54. T.C. Pearson, D.Z. Alexander, R. Hendrix, E.T. Elwood, P.S. Linsley, K.J. Winn and C.P. Larsen, CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism, Transplantation 61 (1996), 997-1004.
55. T.C. Pearson, D.Z. Alexander, K.J. Winn, P.S. Linsley, R.P. Lowry and C.P. Larsen, Transplantation tolerance induced by CTLA4-Ig, Transplantation 57 (1994), 1701-1706.
56. N. Perico, O. Imberti, M. Bontempelli and G. Remuzzi, Immunosuppressive therapy abrogates unresponsiveness to renal allograft induced by thymic recognition of donor antigens, Journal of the American Society of Nephrology 5 (1995), 1618-1623.
57. B.R. Renshaw, W.C. Fanslow, III., R.J. Armitage, K.A. Campbell, D. Liggitt, B. Wright, B.L. Davison and C.R. Maliszewski, Humoral immune responses in CD40 ligand-deficient mice, Journal of Experimental Medicine 180 (1994), 1889-1900.
58. P. Rosenstiel, P. Schramm, S. Isenmann, S. Brecht, C. Eickmeier, E. Burger, T. Herdegen, J. Sievers and R. Lucius, Differential effects of immunophilin-ligands (FK506 and V-10,367) on survival and regeneration of rat retinal ganglion cells in vitro and after optic nerve crush in vivo, Journal of Neurotrauma 20 (2003), 297-307.
59. M.H. Sayegh and L.A. Turka, The role of T-cell costimulatory activation pathways in transplant rejection, New England Journal of Medicine 338 (1998), 1813-1821.
60. K. Shimizu, U. Schonbeck, F. Mach, P. Libby and R.N. Mitchell, Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis, Journal of Immunology 165 (2000), 3506-3518.
61. M. Sho, S.E. Sandner, N. Najafian, A.D. Salama, V. Dong, A. Yamada, K. Kishimoto, H. Harada, I. Schmitt and M.H. Sayegh, New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs, Annals of Surgery 236 (2002), 667-675.
62. S.T. Smiley, V. Csizmadia, W. Gao, L.A. Turka and W.W. Hancock, Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction, Transplantation 70 (2000), 415-419.
63. C.R. Smith, T. Mohanakumar, Y. Shimizu, S. Yu, N. Otomo, Z. Kaleem and M.W. Flye, Brief cyclosporine treatment prevents intrathymic (IT) tolerance induction and precipitates acute rejection in an IT rat cardiac allograft model, Transplantation 69 (2000), 294-299.
64. J.B. Sobol, J.B. Lowe, III., R.K. Yang, S.K. Sen, D.A. Hunter and S.E. Mackinnon, Effects of delaying FK506 administration on neuroregeneration in a rodent model, Journal of Reconstructive Microsurgery 19 (2003), 113-118.
65. J.P. Steiner, M.A. Connolly, H.L. Valentine, G.S. Hamilton, T.M. Dawson, L. Hester and S.H. Snyder, Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A, Nature Medicine 3 (1997), 421-428.
66. J.P. Steiner, G.S. Hamilton, D.T. Ross, H.L. Valentine, H. Guo, M.A. Connolly, S. Liang, C. Ramsey, J.H. Li, W. Huang, P. Howorth, R. Soni, M. Fuller, H. Sauer, A.C. Nowotnik and P.D. Suzdak, Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models, Proceedings of the National Academy of Sciences of the United States of America 94 (1997), 2019-2024.
67. O.A. Sulaiman, J. Voda, B.G. Gold and T. Gordon, FK506 increases peripheral nerve regeneration after chronic axotomy but not after chronic schwann cell denervation, Experimental Neurology 175 (2002), 127-137.
68. K. Tanaka, N. Fujita and N. Ogawa, Immunosuppressive (FK506) and non-immunosuppressive (GPI1046) immunophilin ligands activate neurotrophic factors in the mouse brain, Brain Research 970 (2003), 250-253.
69. P.A. Taylor, C.J. Lees, H. Waldmann, R.J. Noelle and B.R. Blazar, Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions, Blood 98 (2001), 467-474.
70. P.A. Taylor, C.J. Lees, J.M. Wilson, M.J. Ehrhardt, M.T. Campbell, R.J. Noelle and B.R. Blazar, Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions, Blood 100 (2002), 3400-3407.
71. T.Y. Tsui, M.D. Jager, A. Deiwick, H. Aselmann, M. Neipp, S.T. Fan and H.J. Schlitt, Delayed low-level calcineurin inhibition promotes allospecific tolerance induction by posttransplantation donor leukocyte infusion, Transplantation 73 (2002), 1325-1332.
72. L.A. Turka, P.S. Linsley, H. Lin, W. Brady, J.M. Leiden, R.Q. Wei, M.L. Gibson, X.G. Zheng, S. Myrdal and D. Gordon, T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo, Proceedings of the National Academy of Sciences of the United States of America 89 (1992), 11102-11105.
73. E. Udina, D. Ceballos, B.G. Gold and X. Navarro, FK506 enhances reinnervation by regeneration and by collateral sprouting of peripheral nerve fibers, Experimental Neurology 183 (2003), 220-231.
74. E. Udina, D. Ceballos, E. Verdu, B.G. Gold and X. Navarro, Bimodal dose-dependence of FK506 on the rate of axonal regeneration in mouse peripheral nerve, Muscle & Nerve 26 (2002), 348-355.
75. E. Udina, E. Verdu and X. Navarro, Effects of the immunophilin ligand FK506 on nerve regeneration in collagen guides seeded with Schwann cells in rats, Neuroscience Letters 357 (2004), 99-102.
76. E. Udina, J. Voda, B.G. Gold and X. Navarro, Comparative dose-dependence study of FK506 on transected mouse sciatic nerve repaired by allograft or xenograft, Journal of the Peripheral Nervous System 8 (2003), 145-154.
77. H. Xu, D.K. Tadaki, E.A. Elster, L.C. Burkly, J.D. Berning, F. Cruzata, R.L. Kampen, S.P. Montgomery, N.B. Patterson, D.M. Harlan and A.D. Kirk, Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates, Transplantation 74 (2002), 940-943.
78. A.A. Yamada and M.H. Sayegh, The CD154-CD40 costimulatory pathway in transplantation, Transplantation 73 (2002), S36-S39.
79. R.K. Yang, J.B. Lowe, III., J.B. Sobol, D.A. Hunter and S.E. Mackinnon, Dose-dependent effects of FK506 on neuroregeneration in a rat model, Plastic & Reconstructive Surgery 112 (2003), 1832-1840.